Search results
Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
Reuters via Yahoo News· 2 years agoU.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy...
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Benzinga via Yahoo Finance· 1 month agoAfter topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co...
Merck Stock Has Been A Laggard For Seven Months. Is It Staging A Comeback?
Investor's Business Daily· 5 months agoMerck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the...
Merck posts better-than-expected results on Keytruda sales jump
Reuters via AOL· 4 months ago(Reuters) -Merck & Co reported better-than-expected fourth-quarter results on Thursday on strong...
Merck profit tops Wall Street view on strong Keytruda sales
Reuters via Yahoo Finance· 2 years ago(Reuters) -Merck & Co on Thursday reported higher-than-expected second-quarter earnings and revenue...
Merck Scores Major Drug Approval, Easing Pain From Keytruda Patent Expiration
Barrons.com· 3 months agoMerck secured Food and Drug Administration approval for a drug widely expected to be an era-defining...
Merck seeks more deals to prepare for Keytruda's revenue decline
Reuters via Yahoo Finance· 4 months ago(Reuters) -Merck & Co on Thursday said it was in the market for deals of up to around $15 billion as...
Merck scraps third prostate cancer study as Keytruda therapy disappoints
Reuters via Yahoo News· 1 year agoMerck & Co on Tuesday scrapped a late-stage trial of a combination therapy with its cancer drug...
Merck (MRK) Beats on Q3 Earnings & Revenues, Ups 2022 View
Zacks via Yahoo Finance· 2 years agoMerck & Co., Inc. MRK reported third-quarter 2022 adjusted earnings of $1.85 per share, beating the...
Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag
Zacks via Yahoo Finance· 1 year agoThe EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined...